H. LUNDBECK A/S SER.B DK1 (LDBA F) stock market data APIs
€6.0169
0(0%)
as of January 16, 2026
Try our APIs with
free plan!
H. LUNDBECK A/S SER.B DK1 Financial Data Overview
Price chart is built with
Anychart
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. a strategic. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Prev. Close
6.0169
Open
6.0169
High
6.0169
Low
6.0169
52 wk Range
3.692-6.36
Market Cap
5 742 M
P/E Ratio
11.7745
Shares Outstanding
792 M
Revenue
24 078 M
Dividends (Yield)
0.1566
Beta
0.37
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get H. LUNDBECK A/S SER.B DK1 data using free add-ons & libraries
Get H. LUNDBECK A/S SER.B DK1 Fundamental Data
H. LUNDBECK A/S SER.B DK1 Fundamental data includes:
- Net Revenue: 24 078 M
- EBITDA: 7 831 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
H. LUNDBECK A/S SER.B DK1 News
New
Assessing Lundbeck Stock After Strong Three Year Rally and Steady Pharma Growth in 2025
Trying to decide whether to jump into H. Lundbeck stock right now? You are not alone. With the share price closing at 44.92 and making strong upward moves of 3.9% this past week and 12.6% over the pas...
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
Company Logo The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled b...
Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
Company Logo Denmark's pharmaceutical market is projected to grow from US$ 3.81 billion in 2024 to US$ 5.20 billion by 2033, with a CAGR of 3.52%. Key drivers include advanced health data infrastruct...
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight
No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
